Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as compared with imatinib, for the very first-line therapy of CML-CP. 5 hundred and nineteen clients with recently diagnosed CML-CP have been randomly assigned to obtain dasatinib at a dose of a hundred mg at the time everyday (259 https://chelwoodv009rkc0.therainblog.com/profile